141 related articles for article (PubMed ID: 21072244)
1. Doctors and drug companies: still cozy after all these years.
Henry D
PLoS Med; 2010 Nov; 7(11):e1000359. PubMed ID: 21072244
[TBL] [Abstract][Full Text] [Related]
2. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review.
Spurling GK; Mansfield PR; Montgomery BD; Lexchin J; Doust J; Othman N; Vitry AI
PLoS Med; 2010 Oct; 7(10):e1000352. PubMed ID: 20976098
[TBL] [Abstract][Full Text] [Related]
3. Drug detailing in academic medical centers: regulating for the right reasons, with the right evidence, at the right time.
Steinman MA; Schillinger D
Am J Bioeth; 2010 Jan; 10(1):21-3. PubMed ID: 20077331
[No Abstract] [Full Text] [Related]
4. Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing.
Hadland SE; Cerdá M; Li Y; Krieger MS; Marshall BDL
JAMA Intern Med; 2018 Jun; 178(6):861-863. PubMed ID: 29799955
[TBL] [Abstract][Full Text] [Related]
5. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
[TBL] [Abstract][Full Text] [Related]
6. Conflicts of interest between the prescriber, the regulator and the profit maker.
Holmes WF
Clin Microbiol Infect; 2001; 7 Suppl 6():9-11. PubMed ID: 11990693
[TBL] [Abstract][Full Text] [Related]
7. Prescribing.
Palmer K
Practitioner; 1990 Oct; 234(1495):888-90. PubMed ID: 2131447
[No Abstract] [Full Text] [Related]
8. Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing.
Zezza MA; Bachhuber MA
PLoS One; 2018; 13(12):e0209383. PubMed ID: 30566426
[TBL] [Abstract][Full Text] [Related]
9. Financial incentives and the prescription of newer vaccines by doctors in India.
Lodha R; Bhargava A
Indian J Med Ethics; 2010; 7(1):28-30. PubMed ID: 20166294
[No Abstract] [Full Text] [Related]
10. No more free drug samples?
Chimonas S; Kassirer JP
PLoS Med; 2009 May; 6(5):e1000074. PubMed ID: 19434227
[TBL] [Abstract][Full Text] [Related]
11. Compliance: what you need to know.
Evans GRD; Haeck P; Roth M; McGuire M; Glasberg S; Wells J; Costelloe M; Stokes M; Wargo C
Plast Reconstr Surg; 2011 Nov; 128(5):1143-1148. PubMed ID: 22030493
[No Abstract] [Full Text] [Related]
12. Accountable prescribing.
Morden NE; Schwartz LM; Fisher ES; Woloshin S
N Engl J Med; 2013 Jul; 369(4):299-302. PubMed ID: 23883375
[No Abstract] [Full Text] [Related]
13. Influence of free drug samples on prescribing by physicians: A cross sectional survey.
Rafique S; Sarwar W; Rashid A; Sheerin F
J Pak Med Assoc; 2017 Mar; 67(3):465-467. PubMed ID: 28304002
[TBL] [Abstract][Full Text] [Related]
14. Pharma freebies for doctors linked to opioidprescribing habits.
Vogel L
CMAJ; 2019 Feb; 191(7):E202. PubMed ID: 30782649
[No Abstract] [Full Text] [Related]
15. Attitudes and relationship between physicians and the pharmaceutical industry in a public general hospital in Lima, Peru.
De Ferrari A; Gentille C; Davalos L; Huayanay L; Malaga G
PLoS One; 2014; 9(6):e100114. PubMed ID: 24978481
[TBL] [Abstract][Full Text] [Related]
16. Prescribing costs and patterns: authors' response.
Walker J; Mathers N
Br J Gen Pract; 2002 Jul; 52(480):587. PubMed ID: 12120741
[No Abstract] [Full Text] [Related]
17. Evaluating prescribing interventions.
Wong G
Br J Gen Pract; 2002 May; 52(478):412-3. PubMed ID: 12014546
[No Abstract] [Full Text] [Related]
18. Financial ties between authors of the clinical practice guidelines and pharmaceutical companies: an example from Japan.
Saito H; Tani Y; Ozaki A; Sawano T; Shimada Y; Yamamoto K; Tanimoto T
Clin Microbiol Infect; 2019 Nov; 25(11):1304-1306. PubMed ID: 31401175
[No Abstract] [Full Text] [Related]
19. [Editorial: Hebebrand, J., Blanz, B., Herpertz-Dahlmann, B. & Lehmkuhl, G. 2012. Increase in the abundance of medical treatments, ethical principles and conflicts of interest in cooperation with the pharmaceutical industry].
Frank R
Z Kinder Jugendpsychiatr Psychother; 2013 Mar; 41(2):145-9. PubMed ID: 23425616
[No Abstract] [Full Text] [Related]
20. Drug promotion practices: A review.
Jacob NT
Br J Clin Pharmacol; 2018 Aug; 84(8):1659-1667. PubMed ID: 29349812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
